Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis

By sjmartinez • January 8, 2024

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5. PMID: 38188537; PMCID: PMC10768812.

Tags: Dermatology, deucravacitinib, efficacy, mechanism of action, psoriasis, Publications, review, safety, TYK2, tyrosine kinase

Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency vs. Outpatient Care for Pediatric Atopic[...]

Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata

Fu J, Goh C. Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata. Br J Dermatol. 2025 Apr 11:ljaf139. doi: 10.1093/bjd/ljaf139. Epub ahead[...]

Measles Resurgence: What Every Dermatologist Should Know

Freeman E, Li C, Castillo D, Ahuja S, Chiu YE, Elewski B, Goh C, Hu J, Rosmarin D, Trinidad J, Rosenbach M. Measles Resurgence: What[...]